45 results about "Tranilast" patented technology

A method of decreasing neuropathic pain in a mammal, comprising administering to said mammal an effective amount of tranilast for a period of time sufficient to decrease pain.

Methods for treating eye diseases associated with inflammation and / or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.

The present invention relates generally to a method of modulating cellular functioning. More particularly, the present invention relates to a method of modulating B cell functioning, for example B cell proliferation, utilising an IDO- mediated tryptophan metabolite as herein defined (particular examples of such IDO-mediated tryptophan metabolites include 3-hydroxykynurenic acid, 3-hydroxyanthranilic acid, picolinic acid, quinolinic acid and tranilast). The method of the present invention is useful, inter alia, in the treatment and / or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate B cell functioning such as antibody production, autoimmune conditions and B cell proliferation and neoplasias. In a related aspect, the present invention is directed to a method of therapeutically and / or prophylactically treating rheumatoid arthritis via the administration of the above-mentioned compounds.

A method of decreasing neuropathic pain in a mammal, comprising administering to said mammal an effective amount of tranilast for a period of time sufficient to decrease pain.

The present disclosure relates to a synergistic mixture of betamethasone valerate and tranilast combined with a transdermal gel using skin permeation enhancement for application in scars for reducing or preventing the abnormal scar formation, specially keloids and hypertrophic scars. The disclosed synergistic mixture may exhibit permeation enhancing properties. The transdermal gel may include a mixture of silicone, phosphatidylcholine, pracaxi oil, and seje oil; one or more oils having essential fatty acids, behenic acid, oleic acid; one or more skin lipids; a butter having linoleic acid and linolenic acid; and solvents as transdermal penetration enhancers.

Mew tranilast complexes and new tranilast cocrystals are disclosed. These include all tranilast nicotinamide complex, a 1:1 tranilast nicotinamide cocrystal, a 1:1 tranilast saccharin complex, a 1:1 tranilast saccharin cocrystal, a 1:1 tranilast gentisic acid complex, a 1:1 tranilast gentisic acid cocrystal, a 1:1 tranilast salicylic acid complex, a 1:1 tranilast salicylic acid cocrystal, a 1:1 tranilast urea complex, a 1:1 tranilast urea cocrystal, a 1:1 tranilast 4-amtnoben2oic acid complex, a 1:1 tranilast 4-am!nobers2oic acid cocrystal, a 1:1 tranilast 2,4-di′hydroxybenzoic acid complex and a 1:1 tranilast 2,4-dihydroxybenzoic acid cocrystal. Also disclosed are pharmaceutical compositions containing a tranilast complex or cocrystal of the invention and a pharmaceutically acceptable carrier. Methods of treatment using the tranilast complexes and cocrystais as well as the pharmaceutical compositions are disclosed.

The invention relates to crystalline tranilast salts. The crystalline tranilast salts, their preparation and their characterization are described and shown in the figures. The invention relates to pharmaceutical compositions containing a crystalline tranilast salt of the invention and a pharmaceutically acceptable carrier. The invention also relates to methods of treatment and the use of a therapeutically effective amount of a crystalline tranilast salt of the invention for treatment. The invention also relates to a method of preparing a liquid pharmaceutical composition comprising the step of dissolving a crystalline tranilast salt of the invention in a pharmaceutically acceptable solvent and to liquid pharmaceutical compositions prepared according to that method.

The invention discloses application of tranilast-combined anti-tuberculosis medicaments in preparation of a medicament for treating tuberculosis, and at least two of the tranilast-combined anti-tuberculosis medicaments (isonicotinyl hydrazine, rifampicin, pyrazinoic acid amide and ethambutol) are adopted. After the medicament combination is applied for 50 days, a patient can feel that skin damage is obviously alleviated; after the medicament combination is applied for 3 to 4 months, skin damage of the patient almost completely disappears with a speed obviously greater than that of a control group of pure anti-tuberculosis treatment, so that the anti-tuberculosis treatment course is greatly shortened, tissue damage such as atrophic scar formation and pigmentation can be reduced, and no obvious adverse reaction exists, which indicates that the tranilast-combined classical anti-tuberculosis medicaments have a synergistic anti-tuberculosis effect, are capable of obviously shortening the anti-tuberculosis treatment course and enhancing the anti-tuberculosis curative effect when used for resisting the tuberculosis, are good in toleration and relatively high in compliance of patients, free from obvious adverse reaction, and relatively good in clinical curative effect and security, and are expected to become necessary medicaments for combined treatment of the tuberculosis.

The present disclosure relates to a synergistic mixture of betamethasone valerate and tranilast combined with a transdermal gel using skin permeation enhancement for application in scars for reducing or preventing the abnormal scar formation, specially keloids and hypertrophic scars. The disclosed synergistic mixture may exhibit permeation enhancing properties. The transdermal gel may include a mixture of silicone, phosphatidylcholine, pracaxi oil, and seje oil; one or more oils having essential fatty acids, behenic acid, oleic acid; one or more skin lipids; a butter having linoleic acid and linolenic acid; and solvents as transdermal penetration enhancers.

The invention discloses the application of an inhibitor of NLRP3 inflammasome in the preparation of medicine for treating pituitary adenoma and the medicine for treating pituitary adenoma. NLRP3 inflammasome inhibitors are MCC950 or tranilast. Drugs containing NLRP3 inflammasome inhibitors may enable the treatment of pituitary adenomas. NLRP3 inflammasome inhibitors bring good news to patients with pituitary adenomas.

The invention relates to a formula and a preparation process of tranilast emulsifiable paste, relates to a treatment effect in the field of keloids and hypertrophic scars of the tranilast emulsifiable paste, and belongs to the field of medical science and technology. The formula of the tranilast cream comprises the following components in percentage by weight: 0.5%-10% of tranilast; 15%-30% of a cream matrix; 3%-5% of a thickening agent; and the balance purified water. The cream matrix comprises an oil phase liquid and a water phase liquid. The preparation process comprises the following steps: preparing the oil phase liquid; preparing the water phase liquid; and preparing emulsified tranilast dispersion liquid and the like. According to the present invention, the cream containing the tranilast component belongs to an external dosage form, and does not have untoward effects such as dependence, cytotoxicity and the like. The medicine is applied locally and permeates the scar tissue to take effect locally, and the concentration of the medicine for the scar target tissue is higher.